MedicalFoundationOfNC.org Editorial Team | Published April 2026
Editorial Disclosure: This article is an independent editorial comparison and is not medical advice. MedicalFoundationOfNC.org is an independent editorial publication. We may receive compensation if you visit merchant links in this article. All company claims referenced below are attributed to the respective companies and are not adopted as editorial assertions. Pricing and program details are current as of our evaluation date and may change. Verify all information directly with each company before making a purchasing decision.
The decision to start GLP-1 medication for weight management is a clinical one. The decision about which telehealth platform to use is a consumer one — and it requires a different kind of evaluation. Once you and your healthcare provider have determined that GLP-1 therapy is appropriate for your situation, you are left comparing platforms that all claim to offer the same basic thing: licensed providers, legitimate medications, and ongoing support. The differences — in pricing structure, what is included versus what costs extra, pharmacy sourcing, and the depth of medical oversight — are where the real evaluation lives.
This comparison examines four of the most visible telehealth GLP-1 platforms operating in 2026: TrimRx, Hims, Ro, and Found. We evaluate each on the criteria that matter most to a patient making this decision: total cost, transparency, medication options, provider quality, and what you actually get for your money.
Pricing: What You Actually Pay Per Month
Pricing in the telehealth GLP-1 space is more complicated than it appears because platforms use different pricing architectures. Some quote an all-inclusive monthly price. Others separate the membership fee from the medication cost, which means the number on the landing page is not the number on your credit card statement.
TrimRx publishes all-inclusive pricing for its compounded medications. According to its website, compounded semaglutide starts at one hundred ninety-nine dollars per month and compounded tirzepatide starts at three hundred forty-nine dollars per month. The company states these prices include the telehealth consultation, prescription, medication, all injection supplies, shipping, and ongoing medical support. There is no separate membership fee. The company also advertises promotional pricing and multi-month bundle options that may reduce the monthly cost further. For branded medications, prices are substantially higher — Ozempic at one thousand two hundred ninety-nine dollars and Zepbound at one thousand three hundred ninety-nine dollars per month, according to the company's published terms.
Hims uses a membership-plus-medication model. According to publicly available information, the weight loss membership costs thirty-nine dollars for the first month and then auto-renews at one hundred forty-nine dollars per month. Medication costs are billed separately and vary based on the treatment plan prescribed. In March 2026, Hims announced a collaboration with Novo Nordisk to offer branded FDA-approved GLP-1 medications including the Wegovy pill, with prices starting at one hundred forty-nine dollars per month for lower doses. Compounded semaglutide pricing through Hims has varied — the platform previously advertised injectable compounded semaglutide starting at one hundred ninety-nine dollars per month with an annual prepayment, with the month-to-month price reported as significantly higher. The compounded semaglutide pill launched at forty-nine dollars per month in February 2026 but was withdrawn after FDA and HHS pressure and a lawsuit from Novo Nordisk. The total monthly cost through Hims depends heavily on which treatment plan your provider prescribes and which payment structure you select.
Ro also separates membership from medication. The Ro Body membership costs forty-five dollars for the first month and one hundred forty-five dollars per month thereafter. Medication costs are separate and vary. Ro focuses on FDA-approved branded medications — it does not currently offer compounded GLP-1 options. Through manufacturer partnerships, cash-pay medication prices through Ro start at one hundred forty-nine dollars per month for lower-dose Wegovy pill, with higher doses costing more. Ro also offers an insurance concierge service that handles prior authorization paperwork, which can potentially bring the medication cost down to the insurance copay amount. For patients with good commercial insurance coverage, Ro's total monthly cost could be as low as one hundred forty-five dollars (membership) plus a twenty-five to fifty dollar copay. For cash-pay patients without insurance coverage, the total monthly cost is the membership plus the full medication price, which can exceed four hundred dollars per month.
Found describes itself as a full-spectrum metabolic health platform. According to its website, Found partners with medical insurance carriers across the United States, and coverage varies by state and plan. For patients whose insurance is accepted, the program may be significantly more affordable than cash-pay alternatives. For cash-pay patients, Found offers compounded medication options at flat monthly prices, with the specific pricing depending on the treatment plan. Found's published marketing emphasizes personalized treatment with access to more than ten different medication options — not just GLP-1 medications — which distinguishes it from platforms that focus exclusively on semaglutide and tirzepatide.
The telehealth GLP-1 pricing picture has shifted considerably in 2026 — the new Wegovy pill, the Hims-Novo Nordisk collaboration, and the FDA's increased enforcement against misleading compounded GLP-1 marketing have all reshaped what consumers can expect to pay and what they should demand in terms of transparency.
What Is Actually Included: Membership vs. All-Inclusive Models
The difference between what platforms advertise and what you actually receive for your monthly payment is one of the most important factors in this comparison.
TrimRx states that its monthly price includes everything: consultation, medication, injection supplies, shipping, follow-up appointments, dose adjustments, and twenty-four-seven chat support. If accurate, this means there are no additional charges beyond the monthly price for standard care. The company also states there is no monthly membership fee beyond the medication price and that patients can cancel anytime. The simplicity of this model is a genuine advantage for budgeting purposes, though you should confirm the total cost at checkout before committing.
Hims includes provider access, in-app tools, and messaging within its membership fee. Medication, supplies, and shipping are additional. The membership auto-renews monthly. Hims also offers structured weight loss content through its app, but the depth of clinical support versus app-based content varies. Plans are prepaid and nonrefundable after purchase, with plan durations varying by medication type.
Ro includes weekly one-on-one sessions with registered nurses, provider messaging, dose adjustments, and metabolic health lab testing (at Quest locations) within its membership fee. Medication is additional. The nursing support is more structured than what most competitors offer and includes coaching on nutrition, exercise, sleep, and lifestyle changes alongside medication management. Ro also provides an insurance concierge that handles prior authorization paperwork — a service that can save significant time and money for patients whose insurance may cover branded GLP-1 medications.
Found includes access to clinicians trained in obesity medicine, a behavior change program, and an in-app community. The depth of the clinical and behavioral support is a differentiator — Found positions itself as a metabolic health program rather than a medication access platform. Found clinicians can prescribe from a wider range of medications, which means your treatment plan may include non-GLP-1 options if they are more appropriate for your specific biology.
Medication Options and Pharmacy Sourcing
This is where the platforms differ most significantly, and it matters because the type of medication you receive — compounded versus FDA-approved branded — has direct implications for the clinical evidence supporting its use.
TrimRx primarily offers compounded semaglutide and compounded tirzepatide, with branded Zepbound and Ozempic available at higher price points. The company states its compounding pharmacy partners are FDA-regulated and LegitScript-certified. Compounded medications are not FDA-approved as finished products, which means they have not undergone independent clinical trials for safety, effectiveness, or quality as dispensed formulations.
Hims has shifted its approach in 2026. Following the Novo Nordisk collaboration announced in March 2026, Hims now emphasizes FDA-approved branded medications including the Wegovy pill and injectable, as well as Ozempic. Compounded options may still be available for some patients, though the platform has scaled back compounded GLP-1 marketing. The company also offers oral medication kits that may include non-GLP-1 components like metformin and bupropion-naltrexone.
Ro focuses exclusively on FDA-approved branded medications and does not offer compounded GLP-1 options. This means every medication prescribed through Ro has undergone FDA review for safety, effectiveness, and quality — but it also means the cash-pay price is significantly higher than compounded alternatives. Ro has partnered with Eli Lilly to offer Zepbound single-dose vials at a lower price point than the injector pens.
Found offers both compounded and branded medication options, and its wider medication formulary includes non-GLP-1 options. This flexibility allows Found clinicians to match the medication to the patient's specific metabolic profile rather than defaulting to semaglutide or tirzepatide for everyone.
Medical Oversight and Provider Quality
All four platforms state that their providers are licensed in the states where they serve patients. The depth and quality of medical oversight varies.
TrimRx states that care is delivered by licensed U.S. providers and that ongoing support includes dose adjustments and regular check-ins through the patient portal. The published safety information pages are thorough, including full prescribing information for the branded medications and detailed compounded medication disclosures. The specific credentials and specializations of the prescribing providers are not prominently disclosed on the website.
Hims operates through a network of independent licensed providers. The consultation may be asynchronous (questionnaire-based) in most states. Provider access is primarily through messaging within the app, with the option to request video appointments. The breadth of the provider network is substantial given the company's scale as a publicly traded telehealth platform.
Ro offers weekly one-on-one sessions with registered nurses in addition to provider access, which represents a higher frequency of clinical touchpoints than most competitors. Metabolic lab testing is included in the membership, ordered at provider discretion, and covers blood sugar, cholesterol, thyroid function, and kidney function. For patients who want clinical monitoring beyond prescribing and messaging, Ro's model offers more infrastructure.
Found emphasizes that its clinicians are trained in obesity medicine, which is a meaningful distinction. Board certification or training in obesity medicine indicates specialized knowledge of the metabolic, hormonal, and behavioral factors that drive weight management outcomes. Found's program is designed by what it describes as the top obesity specialists in the country, and its clinical protocols include multi-medication options and behavioral programming.
Which Platform Fits Which Patient
Rather than declaring a single winner, the more useful framework is matching the platform to the patient's priorities and circumstances.
TrimRx may be the strongest fit for patients who want the simplest possible pricing model with no separate membership fees, who are comfortable with compounded medications and understand the regulatory distinction from FDA-approved products, who prioritize affordability and want a flat monthly rate that includes everything, and who do not require extensive behavioral coaching or lab monitoring as part of the platform. For a detailed evaluation of TrimRx's specific claims, pricing, and legitimacy indicators, see our full TrimRx review.
Hims may be the strongest fit for patients who want access to FDA-approved branded medications through a well-known, publicly traded telehealth company, who prefer the option to choose between branded and compounded medications, and who value the brand recognition and scale of a major consumer health platform. The ongoing evolution of Hims' product offerings — including the Novo Nordisk partnership and the shifting compounded medication market — means the available options may change. The availability and pricing of specific Hims offerings may change as the Novo Nordisk partnership continues to develop.
Ro may be the strongest fit for patients who have commercial insurance that may cover branded GLP-1 medications and want help navigating prior authorization, who want structured nursing support and metabolic lab monitoring as part of the program, who prefer exclusively FDA-approved branded medications and are willing to pay the higher cost, and who value the insurance concierge service as a differentiator.
Found may be the strongest fit for patients who want a full-spectrum metabolic health approach that goes beyond medication access, who may benefit from non-GLP-1 medication options based on their specific biology, who have insurance coverage that Found accepts, and who value behavioral programming and community support as part of their weight management strategy.
Safety Considerations Across All Platforms
Regardless of which platform you choose, the safety considerations for GLP-1 medications are the same. The medications carry the same side effect profile, the same contraindications, and the same drug interaction potential whether prescribed through TrimRx, Hims, Ro, Found, or any other legitimate provider. The thyroid C-cell tumor boxed warning applies to all GLP-1 receptor agonists. The hypoglycemia risk when combined with insulin or sulfonylureas applies regardless of the prescribing platform. The potential impact on oral contraceptive efficacy from tirzepatide applies no matter where you get the medication.
What varies across platforms is the rigor of the intake screening, the depth of the drug interaction review, and the quality of ongoing monitoring. Our detailed guide to GLP-1 medication safety and drug interactions outlines the specific considerations for patients on cardiovascular, diabetes, and thyroid medications and provides screening questions to ask any platform before starting treatment.
For patients who are still evaluating whether their weight loss situation has reached the point where medical intervention is clinically appropriate, our analysis of weight loss resistance after thirty-five covers the metabolic and hormonal factors that drive treatment-resistant weight loss, and our examination of when conventional approaches fail outlines the clinical thresholds that separate needing-to-try-harder from needing-a-different-tool.
Making Your Decision
The telehealth GLP-1 market in 2026 offers more options, more pricing transparency, and more access than at any point in the category's history. The introduction of oral GLP-1 options, the Hims-Novo Nordisk partnership, and the upcoming Medicare GLP-1 Bridge program launching in July 2026 are all expanding access in meaningful ways. At the same time, the FDA has intensified enforcement against misleading compounded GLP-1 marketing, which is an important regulatory development for consumer safety.
Your decision should be based on your clinical eligibility, your budget and pricing preferences, your comfort level with compounded versus branded medications, the depth of medical oversight you need, and whether insurance coverage makes one platform dramatically more affordable than the others. No platform is universally best. The best platform is the one that matches your specific clinical situation, financial constraints, and support needs.
If you are ready to evaluate TrimRx specifically, view the current TrimRx program details (official TrimRx page) to review the company's published pricing, safety disclosures, and enrollment process directly.
This article is for informational and educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Compounded GLP-1 products are not FDA-approved as finished medications and are not equivalent to FDA-approved branded drugs. Individual results vary based on starting weight, adherence, lifestyle factors, and biology. Prescription approval is not guaranteed on any platform. Pricing and program details are current as of our evaluation date and are subject to change. Always verify information directly with each company before making a purchasing decision. MedicalFoundationOfNC.org is an independent editorial publication and is not responsible for the claims, services, or practices of any third-party company referenced in this article.